Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
1999-8-5
pubmed:abstractText
Analogues based on the insect cecropin-bee melittin hybrid peptide (CEME) were studied and analyzed for activity and salt resistance. The new variants were designed to have an increase in amphipathic alpha-helical content (CP29 and CP26) and in overall positive charge (CP26). The alpha-helicity of these peptides was demonstrated by circular dichroism spectroscopy in the presence of liposomes. CP29 was shown to have activity against gram-negative bacteria that was similar to or better than those of the parent peptides, and CP26 had similar activity. CP29 had cytoplasmic membrane permeabilization activity, as assessed by the unmasking of cytoplasmic beta-galactosidase, similar to that of CEME and its more positively charged derivative named CEMA, whereas CP26 was substantially less effective. The activity of the peptides was not greatly attenuated by an uncoupler of membrane potential, carbonyl cyanide-m-chlorophenylhydrazone. The tryptophan residue in position 2 was shown to be necessary for interaction with cell membranes, as demonstrated by a complete lack of activity in the peptide CP208. Peptides CP29, CEME, and CEMA were resistant to antagonism by 0.1 to 0.3 M NaCl; however, CP26 was resistant to antagonism only by up to 160 mM NaCl. The peptides were generally more antagonized by 3 and 5 mM Mg2+ and by the polyanion alginate. It appeared that the positively charged C terminus in CP26 altered its ability to permeabilize the cytoplasmic membrane of Escherichia coli, although CP26 maintained its ability to kill gram-negative bacteria. These peptides are potential candidates for future therapeutic drugs.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/10390200-118160, http://linkedlifedata.com/resource/pubmed/commentcorrection/10390200-1416876, http://linkedlifedata.com/resource/pubmed/commentcorrection/10390200-1483838, http://linkedlifedata.com/resource/pubmed/commentcorrection/10390200-1693777, http://linkedlifedata.com/resource/pubmed/commentcorrection/10390200-1733777, http://linkedlifedata.com/resource/pubmed/commentcorrection/10390200-2139793, http://linkedlifedata.com/resource/pubmed/commentcorrection/10390200-2455891, http://linkedlifedata.com/resource/pubmed/commentcorrection/10390200-2544449, http://linkedlifedata.com/resource/pubmed/commentcorrection/10390200-2646710, http://linkedlifedata.com/resource/pubmed/commentcorrection/10390200-2668334, http://linkedlifedata.com/resource/pubmed/commentcorrection/10390200-2689223, http://linkedlifedata.com/resource/pubmed/commentcorrection/10390200-2777475, http://linkedlifedata.com/resource/pubmed/commentcorrection/10390200-2999076, http://linkedlifedata.com/resource/pubmed/commentcorrection/10390200-3032093, http://linkedlifedata.com/resource/pubmed/commentcorrection/10390200-3032915, http://linkedlifedata.com/resource/pubmed/commentcorrection/10390200-3105450, http://linkedlifedata.com/resource/pubmed/commentcorrection/10390200-3125111, http://linkedlifedata.com/resource/pubmed/commentcorrection/10390200-3924096, http://linkedlifedata.com/resource/pubmed/commentcorrection/10390200-6048867, http://linkedlifedata.com/resource/pubmed/commentcorrection/10390200-6803666, http://linkedlifedata.com/resource/pubmed/commentcorrection/10390200-6821455, http://linkedlifedata.com/resource/pubmed/commentcorrection/10390200-7341234, http://linkedlifedata.com/resource/pubmed/commentcorrection/10390200-7567965, http://linkedlifedata.com/resource/pubmed/commentcorrection/10390200-7690029, http://linkedlifedata.com/resource/pubmed/commentcorrection/10390200-7840562, http://linkedlifedata.com/resource/pubmed/commentcorrection/10390200-7934902, http://linkedlifedata.com/resource/pubmed/commentcorrection/10390200-8226684, http://linkedlifedata.com/resource/pubmed/commentcorrection/10390200-8332596, http://linkedlifedata.com/resource/pubmed/commentcorrection/10390200-8612275, http://linkedlifedata.com/resource/pubmed/commentcorrection/10390200-8702613, http://linkedlifedata.com/resource/pubmed/commentcorrection/10390200-8945527, http://linkedlifedata.com/resource/pubmed/commentcorrection/10390200-9038346, http://linkedlifedata.com/resource/pubmed/commentcorrection/10390200-9199465, http://linkedlifedata.com/resource/pubmed/commentcorrection/10390200-9465102
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0066-4804
pubmed:author
pubmed:issnType
Print
pubmed:volume
43
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1542-8
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed-meshheading:10390200-Alginates, pubmed-meshheading:10390200-Amino Acid Sequence, pubmed-meshheading:10390200-Animals, pubmed-meshheading:10390200-Anti-Bacterial Agents, pubmed-meshheading:10390200-Antimicrobial Cationic Peptides, pubmed-meshheading:10390200-Carrier Proteins, pubmed-meshheading:10390200-Cell Membrane Permeability, pubmed-meshheading:10390200-Glucuronic Acid, pubmed-meshheading:10390200-Hexuronic Acids, pubmed-meshheading:10390200-Magnesium Chloride, pubmed-meshheading:10390200-Mice, pubmed-meshheading:10390200-Microbial Sensitivity Tests, pubmed-meshheading:10390200-Molecular Sequence Data, pubmed-meshheading:10390200-Protein Structure, Secondary, pubmed-meshheading:10390200-Recombinant Proteins, pubmed-meshheading:10390200-Sodium Chloride, pubmed-meshheading:10390200-Structure-Activity Relationship
pubmed:year
1999
pubmed:articleTitle
Salt-resistant alpha-helical cationic antimicrobial peptides.
pubmed:affiliation
Department of Microbiology and Immunology, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't